RESUMEN
BACKGROUND: Few studies have focused on food allergies in the elderly, even though it may persist or appear de novo. METHODS: We reviewed data for all cases of food-induced anaphylaxis in people age ≥ 60 reported to the French "Allergy Vigilance Network" (RAV) between 2002 and 2021. RAV collates data reported by French-speaking allergists regarding cases of anaphylaxis graded II to IV according to the Ring and Messmer classification. RESULTS: In total, 191 cases were reported, with an even sex distribution and mean age was 67.4 years (range 60 to 93). The most frequent allergens were mammalian meat and offal (31 cases, 16.2%), often associated with IgE to α-Gal. Legumes were reported in 26 cases (13.6%), fruits and vegetables in 25 cases (13.1%), shellfish 25 cases (13.1%), nuts 20 cases (10.5%), cereals 18 cases (9.4%), seeds 10 cases (5.2%), fish 8 cases (4.2%) and anisakis 8 cases (4.2%). Severity was grade II in 86 cases (45%), grade III in 98 cases (52%) and grade IV in 6 cases (3%) with one death. Most episodes occurred at home or in a restaurant and in most cases adrenaline was not used to treat the acute episode. Potentially relevant cofactors such as beta-blocker, alcohol or non-steroidal anti-inflammatory drug intake were present in 61% of cases. Chronic cardiomyopathy, present in 11.5% of the population, was associated with greater, grade III or IV reaction severity (OR 3.4; 1.24-10.95). CONCLUSION: Anaphylaxis in the elderly has different causes to younger people and requires detailed diagnostic testing and individualized care plans.
Asunto(s)
Anafilaxia , Hipersensibilidad a los Alimentos , Animales , Anafilaxia/epidemiología , Anafilaxia/etiología , Anafilaxia/diagnóstico , Epinefrina/uso terapéutico , Carne , Alimentos Marinos , Alérgenos , Verduras , MamíferosRESUMEN
BACKGROUND: Venom-induced anaphylaxis (VIA) is a common, potentially life-threatening hypersensitivity reaction associated with (1) a specific symptom profile, 2) specific cofactors, and 3) specific management. Identifying the differences in phenotypes of anaphylaxis is crucial for future management guidelines and development of a personalized medicine approach. OBJECTIVE: This study aimed to evaluate the phenotype and risk factors of VIA. METHODS: Using data from the European Anaphylaxis Registry (12,874 cases), we identified 3,612 patients with VIA and analyzed their cases in comparison with sex- and age-matched anaphylaxis cases triggered by other elicitors (non-VIA cases [n = 3,605]). RESULTS: VIA more frequently involved more than 3 organ systems and was associated with cardiovascular symptoms. The absence of skin symptoms during anaphylaxis was correlated with baseline serum tryptase level and was associated with an increased risk of a severe reaction. Intramuscular or intravenous epinephrine was administered significantly less often in VIA, in particular, in patients without a history of anaphylaxis. A baseline serum tryptase level within the upper normal range (8-11.5 ng/mL) was more frequently associated with severe anaphylaxis. CONCLUSION: Using a large cohort of VIA cases, we have validated that patients with intermediate baseline serum tryptase levels (8-11 ng/mL) and without skin involvement have a higher risk of severe VIA. Patients receiving ß-blockers or angiotensin-converting enzyme inhibitors had a higher risk of developing severe cardiovascular symptoms (including cardiac arrest) in VIA and non-VIA cases. Patients experiencing VIA received epinephrine less frequently than did cases with non-VIA.
Asunto(s)
Anafilaxia/etiología , Anafilaxia/fisiopatología , Anafilaxia/terapia , Venenos de Artrópodos/efectos adversos , Mordeduras y Picaduras de Insectos/complicaciones , Adulto , Estudios de Casos y Controles , Niño , Estudios de Cohortes , Europa (Continente) , Femenino , Humanos , Masculino , Fenotipo , Sistema de Registros , Factores de RiesgoRESUMEN
OBJECTIVE: Little is known regarding food anaphylaxis in infancy. We aimed to describe specificities of food anaphylaxis in infants (≤12 months) as compared to preschool children (1-6 years). METHODS: We conducted a retrospective study of all food anaphylaxis cases recorded by the Allergy Vigilance Network from 2002 to 2018, in preschool children focusing on infants. RESULTS: Of 1951 food anaphylaxis reactions, 61 (3%) occurred in infants and 386 (20%) in preschool children. Two infants had two anaphylaxis reactions; thus, we analyzed data among 59 infants (male: 51%; mean age: 6 months [SD: 2.9]); 31% had a history of atopic dermatitis, 11% of previous food allergy. The main food allergens were cow's milk (59%), hen's egg (20%), wheat (7%) and peanut (3%) in infants as compared with peanut (27%) and cashew (23%) in preschool children. Anaphylaxis occurred in 28/61 (46%) cases at the first cow's milk intake after breastfeeding discontinuation. Clinical manifestations were mainly mucocutaneous (79%), gastrointestinal (49%), respiratory (48%) and cardiovascular (21%); 25% of infants received adrenaline. Hives, hypotension and neurologic symptoms were more likely to be reported in infants than in preschool children (P = .02; P = .004; P = .002, respectively). Antihistamines and corticosteroids were more often prescribed in preschool children than in infants (P = .005; P = .025, respectively). CONCLUSION: Our study found that in infants presenting with their first food allergy, in a setting with a high rate of infant formula use, the most predominant trigger was cow's milk. As compared to older preschool children, hives, hypotonia and hypotension were more likely to be reported in infants. We believe that this represents a distinct food anaphylaxis phenotype that can further support developing the clinical anaphylaxis criteria in infants.
Asunto(s)
Distribución por Edad , Anafilaxia/epidemiología , Hipersensibilidad a los Alimentos/epidemiología , Anacardium , Anafilaxia/etiología , Anafilaxia/fisiopatología , Angioedema/fisiopatología , Preescolar , Tos/fisiopatología , Llanto , Disnea/fisiopatología , Hipersensibilidad al Huevo/complicaciones , Hipersensibilidad al Huevo/epidemiología , Hipersensibilidad al Huevo/fisiopatología , Femenino , Hipersensibilidad a los Alimentos/complicaciones , Hipersensibilidad a los Alimentos/fisiopatología , Humanos , Hipotensión/fisiopatología , Lactante , Edema Laríngeo/fisiopatología , Masculino , Hipersensibilidad a la Leche/complicaciones , Hipersensibilidad a la Leche/epidemiología , Hipersensibilidad a la Leche/fisiopatología , Hipotonía Muscular/fisiopatología , Hipersensibilidad a la Nuez/complicaciones , Hipersensibilidad a la Nuez/epidemiología , Hipersensibilidad a la Nuez/fisiopatología , Hipersensibilidad al Cacahuete/complicaciones , Hipersensibilidad al Cacahuete/epidemiología , Hipersensibilidad al Cacahuete/fisiopatología , Prurito/fisiopatología , Agitación Psicomotora/fisiopatología , Ruidos Respiratorios/fisiopatología , Estudios Retrospectivos , Convulsiones/fisiopatología , Urticaria/fisiopatología , Vómitos/fisiopatología , Hipersensibilidad al Trigo/complicaciones , Hipersensibilidad al Trigo/epidemiología , Hipersensibilidad al Trigo/fisiopatologíaAsunto(s)
Alérgenos , Anafilaxia , Hipersensibilidad a los Alimentos , Lupinus , Humanos , Anafilaxia/etiología , Anafilaxia/diagnóstico , Anafilaxia/inmunología , Hipersensibilidad a los Alimentos/inmunología , Hipersensibilidad a los Alimentos/diagnóstico , Alérgenos/inmunología , Lupinus/efectos adversos , Lupinus/inmunología , Masculino , Femenino , Inmunoglobulina E/inmunología , Inmunoglobulina E/sangre , AdultoAsunto(s)
Anafilaxia/tratamiento farmacológico , Epinefrina/uso terapéutico , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Población , Instituciones Académicas , Adolescente , Alérgenos/inmunología , Anafilaxia/diagnóstico , Anafilaxia/epidemiología , Niño , Preescolar , Femenino , Alimentos , Hipersensibilidad a los Alimentos/diagnóstico , Hipersensibilidad a los Alimentos/epidemiología , Francia/epidemiología , Humanos , Masculino , Encuestas y CuestionariosRESUMEN
Vaccination against COVID-19 constitutes a huge hope and a major challenge. For the first time in modern history, a global vaccination campaign has started worldwide in a short period of time and with products that were recently developed. Consequently, legitimate concerns regarding the safety and tolerability of COVID-19 vaccines arise.In line with international allergy societies, the Belgian Society for Allergy and Clinical Immunology (BelSACI) provides this statement to guide health care providers (general practitioners, specialists including allergists) and stakeholders.In this statement, we first review current evidence on allergic reactions to vaccines and the potential risk factors that have been identified.Second, we provide a risk stratification method that may be used as a worksheet during the vaccination campaign.Finally, we discuss the management of suspected or confirmed allergic reactions following vaccination.